ADVERTISEMENT

ADVERTISEMENT

NEUROPATÍA AUTONÓMICA DIABÉTICA: MANIFESTACIONES CLÍNICAS POCO CONOCIDAS

Carolina Domínguez, Claudia Flores, Graciela Fuente, Concepción García, Marcela Giménez Rey, Fernanda Huber, Solange Houssay, Maricel Recalde, Raquel Urdaneta

Resumen


La neuropatía crónica es la complicación más prevalente de la diabetes. De las distintas formas de neuropatía diabética, la polineuropatía distal y simétrica y la neuropatía autonómica, particularmente la neuropatía autonómica cardíaca, son las más estudiadas y en ocasiones son asintomáticas.

Los pacientes con prediabetes también pueden desarrollar neuropatías similares a la neuropatía diabética. La prevención es un componente clave en la atención de estas complicaciones.

La neuropatía autonómica diabética afecta varios órganos y sistemas de la economía. Nuestro objetivo es describir aquellas manifestaciones clínicas poco conocidas y en consecuencia poco tenidas en cuenta, que afectan el sistema cardiovascular, el gastrointestinal y el compromiso vesical.


Palabras clave


diabetes; neuropatía autonómica; cardiovascular; gastrointestinal; disfunción vesical.

Texto completo:

PDF

Referencias


Ziegler D, Zentai CP, Perz S, et al.; KORA Study Group. Prediction of mortality using measures of cardiac autonomic dysfunction in the diabetic and nondiabetic population: the MONICA/KORA Augsburg Cohort Study. Diabetes Care 2008; 31:556-561.

Pop-Busui R, Feldman EL, Malik RA, Boulton AJ, Bril V, Freeman R, Sosenko JM, Ziegler D. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care 2017;40:136-154.

Jin HY, Baek HS, Park TS. Morphologic changes in autonomic nerves in diabetic autonomic neuropathy. Diabetes Metab J 2015 Dec; 39(6):461-467. English. Review Published online De-cember 11, 2015. https://doi.org/10.4093/dmj.2015.39.6.461

Actualización en disfunción sexual en pacientes diabéticos. Comité de Neuropatía Diabética de la Sociedad Argentina de Diabetes. Rev Soc Arg Diabetes 2013; 1: 29-39

Vinik A, Erbas T, Casellini CM. Diabetic cardiac autonomic neu¬ropathy, inflammation and cardiovascular disease. J Diabetes Investig 2013 Jan 29; 4(1): 4-18.

Pop-Busui R, Cleary PA, Braffett BH, et al.; DCCT/EDIC Research Group. Association between cardiovascular autonomic neuro¬pathy and left ventricular dysfunction: DCCT/EDIC study (Dia¬betes Control and Complications Trial/ Epidemiology of Diabe¬tes Interventions and Complications). J Am Coll Cardiol 2013; 61:447-454.

Maser RE, Mitchell BD, Vinik AI, et al. The association between cardiovascular autonomic neuropathy and mortality in indi¬viduals with diabetes: a meta-analysis. Diabetes Care 2003; 26:1895-1901.

Pop-Busui R, Evans GW, Gerstein HC, et al.; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of cardiac autonomic dysfunction on mortality risk in the Action to Con¬trol Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care 2010; 33:1578-1584.

Young LH, Wackers FJ, Chyun DA, et al.; DIAD Investigators. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. JAMA 2009; 301:1547-1555.

Vinik A. Diabetic cardiovascular autonomic neuropathy. Circu¬lation 2007; 115:387-397.

Stewart JM, et al. Clinical and physiological effects of an acute alpna-1 adrenergic agonist and a beta-1 adrenergic antagonist in chronic orthostatic intolerance. Circulation 2002; 106, 2946-2954.

Raj SR. Renin-aldosterone paradox and perturbed blood volu¬me regulation underlying postural tachycardia syndrome. Circulation 2005; 111:1574-1582.

Stewart JL. Increased plasma angiotensin II in postural tachy¬cardia syndrome (POTS) is related to reduced blood flow and blood volumen. Clinical Science 2006; 110, 255-263.

Didangelos TP. Left ventricular systolic and diastolic function in normotensive type 1 diabetic patients with or without autonomic neuropathy. Diabetes Care 2003; 26:1955-1960.

Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Circulation 1996; 93: 1043-1065.

Pop-Busui R. Cardiac autonomic neuropathy in diabetes: a clinical perspective. Diabetes Care 2010; 33:434-441.

Pop-Busui R, Low PA, Waberski BH, et al.; DCCT/EDIC Research Group. Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC). Circulation 2009; 119:2886-2893.

Low PA, Benrud-Larson LM, Sletten DM, et al. Autonomic symptoms and diabetic neuropathy: a population-based study. Diabetes Care 2004; 27:2942-2947.

Ziegler D, Keller J, Maier C, et al.; German Diabetes Association. Diabetic neuropathy. Exp Clin Endocrinol Diabetes 2014;122: 406-415.

Freeman R. Clinical practice. Neurogenic orthostatic hypotension. N Engl J Med 2008; 358:615-624.

Spallone V, Bellavere F, Scionti L, et al.; Diabetic Neuropathy Study Group of the Italian Society of Diabetology. Recommendations for the use of cardiovascular tests in diagnosing diabetic autonomic neuropathy. Nutr Metab Cardiovasc Dis 2011; 21:69-78.

Low PA, Gilden JL, Freeman R, et al.; Midodrine Study Group. Efficacy of midodrinevs placebo in neurogenic orthostatic hypotension. A randomized, doubleblind multicenter study. JAMA 1997; 277:1046-1051.

Low PA, Tomalia VA. Orthostatic hypotension: mechanisms, causes, management. J Clin Neurol 2015; 11:220-226.

Folwaczny C, Riepl R, Tschöp M, et al.; Gastrointestinal in volvement in patients with diabetes mellitus: Part I (first of two parts). Epidemiology, pathophysiology, clinical findings. Z Gastroenterol 1999; 37: 803-815.

Zhao J, Frøkjær JB, Drewes AM, et al. Upper gastrointestinal sensory-motor dysfunction in diabetes mellitus. World J Gastroenterol 2006 May 14; 12(18): 2846-2857. www.nature.com/clinicalpractice/gasthep.

Sellin J, Chang E. Therapy Insight: gastrointestinal complications of diabetes pathophysiology and management. Nature Clinical Practice Gastroenterologic & Hepatologis 2008; 5 (3): 162-171.

Tsai SC, Kao CH, Pan DY, et al. Effects oforal erythromycin on esophageal motility in patients with noninsulin-dependent diabetes mellitus. The Kaohsiung Journal of Medical Sciences 1995; 11: 430-435.

Annese V, Bassotti G, Caruso N, et al. Gastrointestinal motor dysfunction, symptoms, and neuropathy in noninsulindependent (type 2) diabetes mellitus. J Clin Gastroenterol 1999; 29: 171-177.

Holloway RH, Tippett MD, Horowitz M, et al. Relationship between esophageal motility and transit in patients with type 1 diabetes mellitus. Am J Gastroenterol 1999; 94: 3150-3157.

Björnsson ES, Urbanavicius V, Eliasson B, Attvall S, Smith U, Abrahamsson H. Effects of hyperglycemia on interdigestive gastrointestinal motility in humans. Scand J Gastroenterol 1994; 29: 1096-1104.

Samsom M, Jebbink RJ, Akkermans LM, van Berge-Henegouwen GP, Smout AJ. Abnormalities of antroduodenal motility in type I diabetes. Diabetes Care 1996; 19: 21-27.

Azpiroz F, Malagelada C. Diabetic neuropathy in the gut: pathogenesis and diagnosis. Diabetologia 2016; 59:404-408.

Yarandi SS, Srinivasan S. Diabetic gastrointestinal motility disorders and the role of enteric nervous system: current status and future directions. Neurogastroenterol Motil 2014; 26:611-624.

Malagelada C, Drozdzal M, Seguí S, et al. Classification of functional bowel disorders by objective physiological criteria based on endoluminal image analysis. Am J Physiol Gastroin-test Liver Physiol 2015; 309:G413-G419.

Malagelada C, De Iorio F, Azpiroz F, et al. New insight into intestinal motor function via non invasive endoluminal image analysis. Gastroenterology 2008; 135:1155–1162

Frøkjaer JB, Andersen SD, Ejskaer N, et al. Gut sensations in diabetic autonomic neuropathy. Pain 2007; 131:320-329.

Azpiroz F. Gastrointestinal perception: pathophysiological implications. Neurogastroenterol Motil 2002; 14:229-239.

Distrutti E, Azpiroz F, Soldevilla A, et al. Gastric wall tension determines perception of gastric distention. Gastroenterology 1999; 116: 1035-1042.

Sellin J, Chang E. Therapy insight: gastrointestinal complications of diabetes pathophysiology and management. Nature Clinical Practice Gastroenterology & Hepatology 2008; 5 (3): 162-171.

Camilleri M, Parkman H. Clinical guideline: management of gastroparesis. Am J Gastroenterol 2013; 108(1): 18-38.

Camilleri M, Buéno L, et al. Pharmacologic, pharmacokinetic, and pharmacogenomic. Aspects of functional gastrointestinal disorders. Gastroenterology 2016; 150:1319-1331.

Poen AC, Felt-Bersma RJ, Van Dongen PA, et al. Effect of prucalopride, a new enterokinetic agent, on gastrointestinal transit and anorectal function in healthy volunteers. Aliment Pharmacol Ther 1999; 13:1493-1497.

Degen L, Matzinger D, Merz M, et al. Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment Pharmacol Ther 2001; 15:1745-1751.

Cremonini F, Delgado-Aros S, Camilleri M. Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Neurogastroenterol Motil 2003; 15:79-86.

Camilleri M. Diabetic gastroparesis. N Engl J Med 2007; 356:820-829.

Panel nacional de expertos sobre la atención de gastroparesia ALAD. Rev ALAD 2017; 7: 9-23

Camilleri M. Appraisal of medium-and long-term treatment of gastro paresis and chronic intestinal dysmotility. Am J Gastroenterol 1994; 89:1769-1774.

Abell TL, Bernstein VK, Cutts T, et al. Treatment of gastroparesis: a multidisciplinary clinical review. Neurogastroenterol Motil 2006; 18:263-283.

Pfeiffer A, Holgl B, Kaess H. Effect of ethanol and commonly ingested alcoholic beverages on gastric emptying and gastrointestinal transit. Clin Investig 1992; 70:487-491.

Sanaka M, Anjiki H, Tsutsumi H, et al. Effect of cigarette smoking on gastric emptying of solids in Japanese smokers: a crossover study using the 13C-octanoic acid breath test. J Gas-troenterol 2005; 40:578-582.

Scott AM, Kellow JE, Eckersley GM, et al. Cigarette smoking and nicotine delay postprandial mouth-cecum transit time. Dig Dis Sci 1992; 37:1544-1547.

Cho YK, Choi MG, Park EY, et al. Effect of mosapride combined with esomeprazole improves esophageal peristaltic function in patients with gastroesophageal reflux disease: a study using high resolution manometry. Dig Dis Sci 2013; 58:1035-1041.

Owczuk R, Twardowski P, Dylczyk-Sommer A, et al. Influence of promethazine on cardiac repolarisation: a double-blind, midazolam-controlled study. Anaesthesia 2009; 64:609-614. PubMed: 19453313.

Patanwala AE, Amini R, Hays DP, et al. Antiemetic therapy for nausea and vomiting in the emergency department. J Emerg Med 2010; 39: 330-336. PubMed: 20022195.

Barrett TW, Di Persio DM, Jenkins CA, et al. A randomized, placebo-controlled trial of ondansetron, metoclopramide, and promethazine in adults. Am J Emerg Med 2011; 29:247-255.

Allen JH, de Moore GM, Heddle R, et al. Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse. Gut 2004; 53:1566-1570.

Wang L. Clinical observation on acupuncture treatment in 35 cases of diabetic gastroparesis. J Tradit Chin Med 2004; 24: 163-165. PubMed: 15510787.

Borgnakke WS, Ylöstalo PV, et al. Effect of periodontal disease on diabetes: systematic review of epidemiologicobservational evidence. J Periodontol 2013; 84:S135-52. Doi:10.1902/jop.2013.1340013.

Borgnakke WS. Hyperglycemia/diabetes mellitus and periodontal infection adversely affect each other. In: Genco RJ, Williams RC, editors. Periodontal disease and overall health: A clinician’s guide. 2º Ed. Yardley, PA: Professional Audience Communications; 2014, 99-122. Disponible en: Http://www.Colgateprofessional.Com/professionaleducation/articles/periodontal-disease-and-overall-health-a-clinicians-guide-secondedition. Accessed: August 22, 2015.

Borgnakke W. Does treatment of periodontal disease influence systemicdisease? Dent Clin North Am 2015; 59(4):n/a. Doi:10.1016/j.cden.2015.06.007.

Borgnakke WS, Chapple IL, Genco RJ, et al. The multi-center randomized controlled trial (RCT) published by the Journal of the American Medical Association (JAMA) on the effect of periodontal therapy onglycated hemoglobin (HbA1c) has fundamental problems. J Evid Based Dent Pract 2014; 14:127-32. Doi:10.1016/j.jebdp.2014.04.017.

American Diabetes Association. Initial evaluation and diabetes management planning. Diabetes Care 2015; 38:S17-9. Doi:10.2337/dc15-S006.

Netto FO, Diniz IM, Grossmann SM, et al. Risk factors in burning mouth syndrome: a case-control study based on patient records. Clin Oral Investig 2011; 15: 571-575. PMID: 20440632.

Lamey PJ, Lamb AB. Prospective study of aetiological factors in burning mouth syndrome. Br Med J (Clin Res Ed) 1988; 296: 1243-1246. PMID: 3133028.

Yilmaz Z, Renton T, Yiangou Y, et al. Burning mouth syndrome as a trigeminal small fibre neuropathy: increased heat and capsaicin receptor TRPV1 in nerve fibres correlates with pain score. J Clin Neurosci 2007; 14: 864-871. PMID: 17582772.

Grushka M, Epstein JB, Gorsky M. Burning mouth syndrome: differential diagnosis. Dermatol Ther 2002; 15287-291. Doi: 10.1046/j.1529-8019.2002.01535.

Forssell H, Jaaskelainen S, Tenovuo O, et al. Sensory dysfunction in burning mouth syndrome. Pain 2002 Sep 99; (1-2): 41-7.

Grushka M, Sessle BJ, Howley TP. Psychophysical assessment of tactile, pain and thermal sensory functions in burning mouth syndrome. Pain 1987 Feb; 28(2):169-84.

Beneng K, Yilmaz Z, Yiangou Y, et al. Sensory purinergic receptor P2X(3) is elevated in burning mouth syndrome. Int J Oral Maxillofac Surg 2010 Apr 24; 815-819.

Friedman DI. Topirimate-induced burning mouth syndrome. Headache 2010 Sep; 50(8):1383-5.

Scala A, Checchi L, Montevecchi M, et al. Update on burning mouth syndrome: overviewand patient management. Crit Rev Oral Biol Med 2003; 14:275-291. PMID: 12907696.

Eusterman VD. Burning mouth syndrome updated. Chief Editor: Arlen D Meyers Feb 07, 2017.

Moore PA, Guggenheimer J, Orchard T. Burning mouth syndromeand peripheral neuropathy in patients with type 1 diabetes mellitus. J Diabetes Complicat 2007; 21: 397-402. Doi:10.1016/j.jdiacomp.

Bajaj S, Prasad S, Gupta A, Singh VB. Oral manifestations in type 2 diabetes and related complications. Indian J Endocrinol Metab 2012;16:777-9. Doi:10.4103/2230-8210.100673.

Arap A, Siqueira SR, Silva CB, et al. Trigeminal pain and quantitative sensory testing in painful peripheral.diabetic neuropathy. Arch Oral Biol 2010; 55:486-93. Doi:10.1016/j.archoral-bio.2010.03.021.

Collin HL, Niskanen L, Uusitupa M, et al. Oral symptoms and signs in elderly patients with type 2 diabetes mellitus. A focus on diabetic neuropathy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000; 90 (3):299-305. Doi:10.1067/moe.2000.107536.

Le Floch JP, Le Lievre G, Verroust J, et al. Factors related to the electric taste threshold in type 1 diabetic patients. Diabet Med 1990; 7:526-31. Doi:10.1111/j.1464-5491.1990.tb01436.x.

Le Floch JP, Le Lievre G, Labroue M, et al. Early detection of diabetic patients at risk of developing degenerative complications using electric gustometry: a five-year follow-up study. Eur J Med 1992; 1:208-14.

Abbasi AA. Diabetes: diagnostic and therapeutic significance oftaste impairment. Geriatrics 1981; 36:73-4.

Stolbova K, Hahn A, Benes B, et al. Gustometry of diabetes mellitus patients and obese patients. Int Tinnitus J 1999; 5:135-40.

Fomina EI, Pozharitskaia MM, Davydov AL, et al. Changes of gustatory perception inelderly patients with type II sugar diabetes. Surgical section. Russian. Stomatologia (Mosk) 2007; 86:30-4.

Eusterman VD. Burning mouth syndrome updated. Chief Editor: Arlen D Meyers Feb 07, 2017.

Miziara I, Chagury A, Vargas C, et al. Therapeutic options in idiopathic burning mouth syndrome: literature review. Int Arch Otorhinolaryngol 2015 Jan; 19 (1):86-9.

Brown JS, Wessells H, Chancellor MB, et al. Urologic complications of diabetes. Diabetes Care 2005 Jan; 28(1):177-85.

Kebapci N, Yenilmez A, Efe B, et al. Bladder dysfunction in type 2 diabetic Patients. Neurourol Urodyn 2007; 26(6):814-9.

Moller CF, Olesen KP. Diabetic cystopathy. IV: Micturition cystourethrography compared with urodynamic investigation. Dan Med Bull 1976 Dec; 23 (6): 291-4.

Yuan Z, Tang Z, He C, et al. Diabetic cystophaty: a review. J Diabetes 2015 Jul; 7(4):442-7. Doi: 10.1111/1753-0407.12272. Epub 2015 Mar 24. Review.

Liu G, Daneshgari F. Diabetic bladder dysfunction. Chin Med J (Engl). 2014; 127(7):1357-64. Review.

Golbidi S, Laher I. Bladder dysfunction in diabetes mellitus. Front Pharmacol 2010 Nov 16; 1:136.

Peters SL, Schmidt M, Michel MC. Rho kinase: a target for treating urinary bladder dysfunction? Trends Pharmacol Sci 2006; 27, 492-497.

Tammela L, Briscoe JA, Levin RM, et al. Factors underlying the increased sensitivity to field stimulation of urinary bladder strips from streptozotocin-induced diabetic rats. Br J Pharmacol 1994; 113,195-203.

Waring JV, Wendt IR. Effects of streptozotocin-induced diabetes mellitus on intracellular calcium and contraction of longitudinal smooth muscle from rat urinary bladder. J Urol 2000; 163, 323-330.

Changolkar AK, Hypolite JA, Disanto M, et al. Diabetes induced decrease in detrusor smooth muscle force is associated with oxidative stress and overactivity of aldose reductase. J Urol 2005; 173, 309-313.

Daneshgari F, Liu G, Birder L, et al. Diabetic bladder dysfunction: current translational knowledge. J Urol 2009; 182,S18-S26.

Apodaca G, Kiss S, Ruiz W, et al. Disruption of bladder epithelium barrier function after spinal cord injury. Am J Physiol Renal Physiol 2003; 284, F966-F976.

Yoshimura N, Chancellor MB, Andersson KE, et al. Recent advances in understanding the biology of diabetes-associated bladder complications and novel therapy. BJU Int 2005; 95, 733-738.

Mamas MA, Reynard JM, Brading AF. Nitric oxide and the lower urinary tract: current concepts, future prospects. Urology 2003; 61, 1079-1085.

Van Poppel H, Stessens R, Van Damme B, et al. Diabetic cystopathy: neuropathological examination of urinary bladder biopsies. Eur Urol 1998; 15, 128-131.

Steers WD, Tuttle JB. Mechanisms of disease: the role of nerve growth factor in the pathophysiology of bladder disorders. Nat Clin Pract Urol 2006; 2, 101-110.




Copyright (c) 2018 Sociedad Argentina de Diabetes Asociación Civil

ADVERTISEMENT

ADVERTISEMENT